Deerfield Management Company »

Peregrine Pharmaceuticals shares owned by Deerfield Management Company

Quarter-by-quarter ownership of Peregrine Pharmaceuticals (CDMO) shares owned by Deerfield Management Company from 13F filings

Historical chart of Deerfield Management Company investment in Peregrine Pharmaceuticals

Tip: Access up to 7 years of quarterly data

All positions including Peregrine Pharmaceuticals held by Deerfield Management Company consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Peregrine Pharmaceuticals by Deerfield Management Company

Quarter filed Position value Share count Share price at filing
2023-12-31 $257k 40k 6.50

More positions owned by Deerfield Management Company

Nuvalent Inc-a (NUVL)
Glaukos Corp Note 2.750% 6/1 (Principal)
Viatris (VTRS)
Invitae Corp Debt 4.500% 3/1 (Principal)
Natera Note 2.250% 5/0 (Principal)
Catalyst Pharmaceutical Partners (CPRX)
Centene Corporation (CNC)
Brookdale Sr Living Note 2.000%10/1 (Principal)
Insmed Note 1.750% 1/1 (Principal)
Neurocrine Biosciences (NBIX)
Accolade Note 0.500% 4/0 (Principal)
Oscar Health Cl A (OSCR)
Owens & Minor (OMI)
Adapthealth Corp Common Stock (AHCO)
Springworks Therapeutics (SWTX)

View all positions for Deerfield Management Company

Top funds holding Peregrine Pharmaceuticals

Millennium Management
Vanguard Group
AltraVue Capital
Royal Bank of Canada
Palisade Capital Management
Wellington Management Company
Punch & Associates Investment Management
AWM Investment Company
Kornitzer Capital Management
New York State Common Retirement Fund
Dimensional Fund Advisors
Sargent Investment Group
Goldman Sachs Group
B. Riley Asset Management
Two Sigma Investments

View all funds holding Peregrine Pharmaceuticals